AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...
pharmaphorum6d
So it begins: Next Humira biosimilars launch in US
This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many ... aiming to cut injection volume by half and result in fewer injections in particular ...
Hosted on MSN25d
AbbVie retains Humira market share above 70%: report
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70% ... The anti-inflammatory injection, also known as adalimumab, lost its U.S ...
BioSpace3d
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Seeking Alpha25d
AbbVie keeps Humira lead as biosimilar entry nears two-year mark
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70% ... The anti-inflammatory injection, also known as adalimumab, lost its U.S ...